State of Alaska Department of Revenue’s Protagonist Therapeutics PTGX Stock Holding History

State of Alaska Department of Revenue’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.44M	Sell	28,084 -9,063	-24%	-$947K	0.03%	445
2026 Q1	$3.91M	Sell	37,147 -952	-2%	-$84.3K	0.04%	395
2025 Q4	$3.33M	Buy	38,099 +8,674	+29%	+$710K	0.04%	464
2025 Q3	$1.95M	Sell	29,425 -7,481	-20%	-$425K	0.02%	734
2025 Q2	$2.04M	Buy	36,906 +3,883	+12%	+$186K	0.02%	702
2025 Q1	$1.6M	Sell	33,023 -848	-3%	-$35.5K	0.02%	786
2024 Q4	$1.31M	Buy	33,871 +256	+0.8%	+$11.2K	0.01%	916
2024 Q3	$1.51M	Buy	+33,615	New	+$1.36M	0.02%	851

Other funds holding PTGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

State of Alaska Department of Revenue's PTGX Position: Q2 2026 in Review

State of Alaska Department of Revenue reduced its Protagonist Therapeutics (PTGX) stake by 24% in Q2 2026, selling an estimated $947K and leaving 28,084 shares worth $3.44M. The position accounts for 0.03% of the portfolio, ranked #445.

State of Alaska Department of Revenue first reported a position in PTGX in Q3 2024 and has held it in 8 quarters since. The position peaked at $3.91M in Q1 2026. 200 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

State of Alaska Department of Revenue held 28,084 shares of Protagonist Therapeutics worth $3.44M as of Q2 2026.
State of Alaska Department of Revenue sold 9,063 Protagonist Therapeutics shares in Q2 2026, an estimated $947K.
Protagonist Therapeutics made up 0.03% of State of Alaska Department of Revenue's portfolio in Q2 2026, its #445 holding.
State of Alaska Department of Revenue first reported a position in Protagonist Therapeutics in Q3 2024 and has held it in 8 quarters since.
State of Alaska Department of Revenue's Protagonist Therapeutics position peaked at $3.91M in Q1 2026.
200 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on State of Alaska Department of Revenue's 13F filing for Q2 2026, filed 20 Jul 2026.